Research ExplorerPublicationsReceptor tyrosine kinase MET as potential target of multi-ki...

Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC

Standard

Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. / Beizaei, Kaweh; Gleißner, Lisa; Hoffer, Konstantin; Bußmann, Lara; Vu, Anh Thu; Steinmeister, Leonhard; Laban, Simon; Möckelmann, Nikolaus; Münscher, Adrian; Petersen, Cordula; Rothkamm, Kai; Kriegs, Malte.

In: HEAD NECK-J SCI SPEC, Vol. 41, No. 1, 01.2019, p. 208-215.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Beizaei, K, Gleißner, L, Hoffer, K, Bußmann, L, Vu, AT, Steinmeister, L, Laban, S, Möckelmann, N, Münscher, A, Petersen, C, Rothkamm, K & Kriegs, M 2019, 'Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC', HEAD NECK-J SCI SPEC, vol. 41, no. 1, pp. 208-215. https://doi.org/10.1002/hed.25440

APA

Beizaei, K., Gleißner, L., Hoffer, K., Bußmann, L., Vu, A. T., Steinmeister, L., Laban, S., Möckelmann, N., Münscher, A., Petersen, C., Rothkamm, K., & Kriegs, M. (2019). Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. HEAD NECK-J SCI SPEC, 41(1), 208-215. https://doi.org/10.1002/hed.25440

Vancouver

Beizaei K, Gleißner L, Hoffer K, Bußmann L, Vu AT, Steinmeister L et al. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. HEAD NECK-J SCI SPEC. 2019 Jan;41(1):208-215. https://doi.org/10.1002/hed.25440

Bibtex

@article{0504ce7456ee410489f540a8923a7b56,
title = "Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC",
abstract = "BACKGROUND: The multi-kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those kinases to determine the mechanism of sorafenib-mediated effects and establish candidate biomarkers for patient stratification.METHODS: The effects of sorafenib and MET inhibitors crizotinib and SU11274 were analyzed using a slide-based antibody array, Western blotting, proliferation, and survival assays. X-rays were used for irradiations.RESULTS: Sorafenib inhibited auto-phosphorylation of epidermal growth factor receptor and MET, which has not been described previously. MET expression in HNSCC cells was not always associated with activity/phosphorylation. Furthermore, sorafenib-dependent cell kill and radiosensitization was not associated with MET level. Although MET inhibitors blocked proliferation, they caused only mild cytotoxicity and no radiosensitization.CONCLUSION: We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.",
keywords = "Journal Article",
author = "Kaweh Beizaei and Lisa Glei{\ss}ner and Konstantin Hoffer and Lara Bu{\ss}mann and Vu, {Anh Thu} and Leonhard Steinmeister and Simon Laban and Nikolaus M{\"o}ckelmann and Adrian M{\"u}nscher and Cordula Petersen and Kai Rothkamm and Malte Kriegs",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = jan,
doi = "10.1002/hed.25440",
language = "English",
volume = "41",
pages = "208--215",
journal = "HEAD NECK-J SCI SPEC",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC

AU - Beizaei, Kaweh

AU - Gleißner, Lisa

AU - Hoffer, Konstantin

AU - Bußmann, Lara

AU - Vu, Anh Thu

AU - Steinmeister, Leonhard

AU - Laban, Simon

AU - Möckelmann, Nikolaus

AU - Münscher, Adrian

AU - Petersen, Cordula

AU - Rothkamm, Kai

AU - Kriegs, Malte

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2019/1

Y1 - 2019/1

N2 - BACKGROUND: The multi-kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those kinases to determine the mechanism of sorafenib-mediated effects and establish candidate biomarkers for patient stratification.METHODS: The effects of sorafenib and MET inhibitors crizotinib and SU11274 were analyzed using a slide-based antibody array, Western blotting, proliferation, and survival assays. X-rays were used for irradiations.RESULTS: Sorafenib inhibited auto-phosphorylation of epidermal growth factor receptor and MET, which has not been described previously. MET expression in HNSCC cells was not always associated with activity/phosphorylation. Furthermore, sorafenib-dependent cell kill and radiosensitization was not associated with MET level. Although MET inhibitors blocked proliferation, they caused only mild cytotoxicity and no radiosensitization.CONCLUSION: We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.

AB - BACKGROUND: The multi-kinase inhibitor sorafenib displays antitumoral effects in head and neck squamous cell carcinoma (HNSCC); however, the targeted kinases are unknown. Here we aimed to identify those kinases to determine the mechanism of sorafenib-mediated effects and establish candidate biomarkers for patient stratification.METHODS: The effects of sorafenib and MET inhibitors crizotinib and SU11274 were analyzed using a slide-based antibody array, Western blotting, proliferation, and survival assays. X-rays were used for irradiations.RESULTS: Sorafenib inhibited auto-phosphorylation of epidermal growth factor receptor and MET, which has not been described previously. MET expression in HNSCC cells was not always associated with activity/phosphorylation. Furthermore, sorafenib-dependent cell kill and radiosensitization was not associated with MET level. Although MET inhibitors blocked proliferation, they caused only mild cytotoxicity and no radiosensitization.CONCLUSION: We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.

KW - Journal Article

U2 - 10.1002/hed.25440

DO - 10.1002/hed.25440

M3 - SCORING: Journal article

C2 - 30552828

VL - 41

SP - 208

EP - 215

JO - HEAD NECK-J SCI SPEC

JF - HEAD NECK-J SCI SPEC

SN - 1043-3074

IS - 1

ER -